Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570942 | 0.81 | CTSA (0.36) | CTSA | |
| SCHEMBL7561352 | 0.74 | KDM4E (0.46) | TSHRCTSA | |
| SCHEMBL7562568 | 0.73 | CTSA (0.36) | SMN1; SMN2NPC1KMT2ACTSA | |
| SCHEMBL18158008 | 0.69 | KMT2A (0.40) | SMN1; SMN2NPC1KMT2ACTSAHTT | |
| SCHEMBL18157974 | 0.68 | MME (0.32) | KMT2A | |
| SCHEMBL7567595 | 0.67 | TSHR (0.54) | CYSLTR1TSHRSMN1; SMN2NPC1TRPV3 | |
| SCHEMBL18158012 | 0.66 | CPB2 (0.43) | ITGB1ITGA5XIAP | |
| SCHEMBL21266089 | 0.64 | TSHR (0.48) | ITGB1ITGA5TSHRSMN1; SMN2NPC1 | |
| SCHEMBL28804838 | 0.63 | SMN1; SMN2 (0.48) | FOLH1TSHRSMN1; SMN2NPC1KMT2A | |
| SCHEMBL19419036 | 0.63 | FOLH1 (0.50) | FOLH1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 | LTA4H 1754/4885ITGB1 2007/4885ITGA5 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.